At the 25th meeting of the European Group for Blood and Marrow Transplantation in Hamburg, Germany, I gave a presentation about 'Organizational Development in Blood and Marrow Transplants' to familiarize the transplant community with a structure from which academic clinical research in blood and marrow transplants could benefit in the next century in the light of security issues and economics involved in clinical research.
In the early 1970s, approximately 10 years after the first hematopoietic cell transplants, transplant registries were established at academic centers in order to conduct retrospective research to establish the role of high-dose chemo/radiotherapy for treatment of malignancies. Investigators then decided to collaborate and study groups were formed to conduct prospective clinical research. In addition, associations for blood and marrow transplants were established and journals solely dedicated to this topic were established.
These efforts are honorable but none fully covers the scope of academic clinical research opportunities, nor do they evaluate the data collected in registries to a full extent. At least five additional research opportunities could be developed: (1) strategic planning of investigator initiated phase II/III studies based on evidence provided by analysis of existing (literature and registry) data; (2) use of historical registry data to support strategic planning of industry-sponsored phase II/III studies; (3) collection of concurrent data by registries as control cohort for pivotal corporate phase II studies to support accelerated development of new technologies and treatment strategies; (4) inter-academic multicenter phase II/III studies to develop academically derived technologies/treatment strategies with market potential that appear safe in phase I; (5) provision of contract research services to companies developing technologies and treatment strategies suitable for transplantation and cell therapy.
The existing group structures, associations and registries provide insufficient capabilities to support these advanced developments. The ideal structure to encompass existing research activities and develop new research opportunities would be a scientific non-profit clinical and contract research organization. Such an organization should, in view of the logistics and economics involved in clinical research, be developed on a continental basis and be governed by a non-profit making board, consisting of representatives from the academic, non-profit and for-profit sectors. The organization should have a central office headed by an executive director. Existing facilities could become subsidiaries of the central location; guidelines for standard operating procedures should be established and similar procedures be used at all locations. Intercontinental collaboration could occur according to contract and be governed by an umbrella organization. The central office would coordinate and facilitate aspects of research (medical affairs, biostatistics) conducted at the various locations, provide regulatory support and quality assurance and control of operations, be the main information technology and data management center for prospective studies, be the financial center for all research activities and be responsible for contract negotiations and fundraising and take care of developmental activities including marketing, business development, public relations and conference management. The organization would serve as an interface between the virtual academic and industrial sectors, funnel activities, take care of due diligence thereby offering better security for data, scientific endeavors and intellectual property and protect against private/individual and shareholders wealth, frequently so destructive to scientific development.
The mission of these continental organizations should be to identify and develop superior treatment strategies by conduct of clinical research using transplant procedures and cell therapy for malignant and non-malignant, life-threatening diseases with the primary goal to improve patient care.
In summary, the organization could offer new opportunities to investigator-initiated studies, expand industrysponsored studies, support transplant centers, assure respectable use of data, provide contract research and technology/treatment development services, offer education and information services to all those involved in health care in transplantation, serve as a network for transplanters per continent, take care of business aspects and reinvest generated funds to develop the organization and its objectives in support of academic clinical research in the 2000s under the auspices of the American Society for Blood and Marrow Transplantation and the European Group for Blood and Marrow Transplants. The organization could thereby become a recognized continental economic entity in blood and marrow transplants which introduces a competitive advantage compared to existing structures.
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